Skip to Content

Join the 'Repatha' group to help and get support from people like you.

Repatha News

Amgen Makes Repatha (Evolocumab) Available in the U.S. at a 60 Percent Reduced List Price

Posted 25 Oct 2018 by Drugs.com

THOUSAND OAKS, Calif., Oct. 24, 2018 /PRNewswire/ – Amgen (NASDAQ: AMGN) today announced that it is making Repatha (evolocumab), an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and strokes, available at a reduced list price of $5,850 per year. This 60 percent reduction from the medicine's original list price will improve affordability by ...

FDA Approves Amgen's Repatha (evolocumab) to Prevent Heart Attack and Stroke

Posted 12 Dec 2017 by Drugs.com

THOUSAND OAKS, Calif., Dec. 1, 2017 /PRNewswire/ – Amgen (NASDAQ: AMGN) today announced that following priority review of its supplemental Biologics License Application, the U.S. Food and Drug Administration (FDA) approved Repatha (evolocumab) as the first PCSK9 inhibitor to prevent heart attacks, strokes and coronary revascularizations in adults with established cardiovascular disease.1 "We ...

Many Patients Denied Costly New Cholesterol Drugs

Posted 28 Sep 2017 by Drugs.com

THURSDAY, Sept. 28, 2017 – Expensive new medicines offer hope to patients with uncontrolled "bad" cholesterol, but the high cost keeps many patients from getting them, a new study says. The injectable drugs – approved for use in the United States in 2015 – are known as PCSK9 inhibitors. They include Praluent (alirocumab) and Repatha (evolocumab). But, researchers found, of tens of thousands of ...

New Cholesterol Drugs Vastly Overpriced, Study Contends

Posted 22 Aug 2017 by Drugs.com

TUESDAY, Aug. 22, 2017 – Are new medicines for people with out-of-control cholesterol wildly overpriced? It's a question that's sparking debate among consumers and providers of care. Now, researchers at the University of California, San Francisco (UCSF) report that the price of these drugs – called PCSK9 inhibitors – would have to be slashed by a whopping 71 percent to be deemed ...

Powerful New Cholesterol Med Won't Harm Memory, Easing Concerns

Posted 17 Aug 2017 by Drugs.com

WEDNESDAY, Aug. 16, 2017 – Despite some early concerns, a new study suggests the powerful cholesterol drugs known as PCSK9 inhibitors may not cause memory problems or other mental symptoms. The drugs, which include evolocumab (Repatha) and alirocumab (Praluent), were approved in the United States in 2015. That came after trials showed they can dramatically slash LDL cholesterol (the "bad" kind), ...

New Cholesterol Drugs May Beat Statins, But Price Tag Is High

Posted 17 Mar 2017 by Drugs.com

FRIDAY, March 17, 2017 – Two different injectable drugs can lower cholesterol levels even further than statins do, potentially warding off future heart attacks or strokes, new research suggests. However, some heart experts question whether the pricey medications, one of which costs roughly $14,000 a year to take, perform well enough to make them worth the extra money. In fact, some cardiologists ...

Study Suggests Newer Cholesterol Drugs Are Safe

Posted 31 Jan 2017 by Drugs.com

MONDAY, Jan. 30, 2017 – A combination of drugs that drastically lowers "bad" cholesterol levels appears safe for heart patients, but whether it prevents heart attacks or strokes isn't yet known, researchers report. "It may be that people need very low cholesterol levels to get a benefit in terms of heart attacks and stroke reduction, but that remains to be determined," said lead researcher Dr. ...

Coming Soon: Lower Cholesterol From a Twice-a-Year Shot?

Posted 15 Nov 2016 by Drugs.com

TUESDAY, Nov. 15, 2016 – Instead of popping a pill every day, people might soon control "bad" LDL cholesterol by getting an injection at their doctor's office two or three times a year. Researchers testing a new injectable drug called Inclisiran found it cut LDL cholesterol by half or more. According to early clinical trial data, the effect could last for four to six months. Inclisiran produced ...

Are There Alternatives to Statins?

Posted 27 Sep 2016 by Drugs.com

TUESDAY, Sept. 27, 2016 – Statins are the go-to therapy for lowering "bad" LDL cholesterol, but other treatments also can effectively reduce risk of future heart problems, a new evidence review reports. These alternative therapies – including a heart-healthy diet, other cholesterol-lowering medications, and even intestinal bypass surgery – seem to confer the same level of heart health ...

FDA Approves Repatha (evolocumab) Pushtronex - First And Only Single Monthly Injection for a PCSK9 Inhibitor

Posted 1 Aug 2016 by Drugs.com

THOUSAND OAKS, Calif., July 11, 2016 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha® (evolocumab) Pushtronex™ system (on-body infusor with prefilled cartridge), a new, monthly single-dose administration option.1 The Pushtronex system is a hands-free device designed to provide 420 mg of Repatha in a single dose. Repatha ...

Negative News on Statins Tied to Dropped Prescriptions

Posted 2 Dec 2015 by Drugs.com

WEDNESDAY, Dec. 2, 2015 – News reports on the downsides of statins may push some people to stop taking the cholesterol-lowering drugs, a new study hints. The findings, published Dec. 2 in the European Heart Journal, cannot prove that media stories drive statin users to give up their prescriptions. Instead, Danish researchers found a broad correlation between "negative" media coverage and ...

Heart Disease Doesn't Take a Holiday

Posted 25 Nov 2015 by Drugs.com

WEDNESDAY, Nov. 25, 2015 – People with heart disease should take a number of precautions if they travel over the Thanksgiving holiday, an expert suggests. The first step is to be as well-prepared on your trip as you are at home, said Dr. Winston Gandy Jr., a cardiologist at Piedmont Heart Institute in Atlanta. "Make sure when you travel that you have your medicine," Gandy said in an American ...

FDA Approves Repatha for High Cholesterol

Posted 31 Aug 2015 by Drugs.com

FRIDAY, Aug. 28, 2015 – Repatha (evolocumab) has been approved by the U.S. Food and Drug Administration, the second non-statin drug in its class approved to treat high cholesterol. The injected drug, among a new class called PCSK9 inhibitors, is sanctioned for people who are unable to reduce levels of the so-called LDL "bad" cholesterol with statin therapy and exercise, the agency said in a news ...

FDA Approves Repatha - Second Drug in New Class of Cholesterol-Lowering Medications

Posted 31 Aug 2015 by Drugs.com

THURSDAY, Aug. 27, 2015 – The U.S. Food and Drug Administration on Thursday approved a second drug that's part of a potent new class of medications that sharply cut levels of "bad" LDL cholesterol. Repatha (evolocumab), an injectable drug, works by blocking a protein that interferes with the liver's ability to remove LDL cholesterol from the blood. In July, the FDA approved Praluent ...

FDA Approves Repatha (evolocumab) to Treat Certain Patients with High Cholesterol

Posted 31 Aug 2015 by Drugs.com

August 27, 2015 – The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current treatment options. Repatha, the second drug approved in a new class of drugs known as PCSK9 inhibitors, is approved for use in addition to diet and maximally-tolerated statin ...

Ask a Question

Further Information

Related Condition Support Groups

High Cholesterol - Familial Heterozygous, Cardiovascular Risk Reduction, High Cholesterol, High Cholesterol - Familial Homozygous

Repatha Patient Information at Drugs.com